One Film, Many Formulas: How Strip-Based Coating Turns Multi-Formula ODFs into Scalable Reality
Share
Fixed-dose combinations (FDCs), multi-ingredient functional ODFs (for example, multivitamins, probiotic blends, or herbal combinations) are no longer just a concept. Regulators and patients increasingly expect combination therapies and convenient single-dose formats – which means more projects where one oral film needs to carry more than one formula.
However, when these projects move from R&D to GMP-scale manufacturing, every extra process step adds variability, waste and validation complexity. The real question becomes: Can we put multiple formulas on one film in a way that is stable, efficient and truly scalable?
HUANGHAI’s strip-based multi-formula coating approach, powered by patent CN117323228A , was designed to answer exactly this question.
Trend: One Film, Multiple Formulas
Market demand is shifting from simple, single-API ODFs toward:
- Fixed-dose combinations (FDCs) that combine multiple actives in one strip.
- Multi-ingredient functional ODFs – for example, vitamins plus probiotics, or botanicals plus minerals.
- Segmented films where different lanes or zones carry different strengths or ingredient sets.
From a formulation point of view, many of these concepts are achievable in the lab. The bottleneck comes later: how to turn a smart bench-top idea into a repeatable, GMP-ready manufacturing process.
Pain Points in Conventional ODF Manufacturing
Traditional ODF production often follows a familiar sequence: wide-web coating → edge trimming → longitudinal slitting → cross-cutting. This works well for single-formula films, but when you try to run multiple formulas in parallel, several problems are amplified:
- Significant material waste: High-value APIs and excipients end up in edge trims and offcuts during slitting and re-shaping.
- Consistency risks: Multiple coating runs or secondary lamination steps can introduce dosage variation, lane-width drift and edge defects.
- Complex validation: More steps mean more critical parameters to define and monitor, making batch-to-batch variation harder to explain during audits.
In other words, the more you rely on secondary slitting and reshaping to “create” multi-formula strips, the harder it becomes to control yield, uniformity and regulatory risk at commercial scale.
This is precisely the pain point targeted by CN117323228A: using a strip-based coating structure so that multi-formula lanes are formed directly in the coating step, instead of being carved out later.
HUANGHAI’s Answer: Strip-Based Multi-Formula Coating
HUANGHAI’s multi-formula strip coating solution is built on the patented Slitting-Type Film Coating Device (CN117323228A) . Instead of coating a full-width web and then cutting it down, the system is engineered to shape each strip at the coating stage itself.
1. Multi-Channel Feed and Structured Strip Geometry
At the heart of the system is a multi-channel feed manifold with dedicated supply grooves for each formulation. Each channel defines its own target lane on the substrate, including width and spacing.
This design allows:
- Different formulas to run in parallel lanes on the same web.
- Strip width to be geometrically constrained by the coating hardware, not left entirely to downstream slitting.
- Adjustments to be made at the coating head (lane width, pattern, layout) instead of adding more post-processing steps.
2. Less Reliance on Downstream Slitting
Because the film already emerges from the coater in a structured, multi-lane layout, downstream operations can focus on simple, aligned cutting and packaging instead of heavy reshaping. This directly reduces:
- Edge trim waste and “sacrificed” lanes.
- Opportunities for lateral strip drift and lane-width variability.
- The number of critical control points that must be validated and monitored.
3. Better Fit for GMP Scale-Up
By removing redundant steps from the process, the strip-based approach makes the manufacturing route:
- Shorter: Fewer unit operations and less handling.
- Easier to validate: Key parameters are concentrated at the coater and dryer, where they can be tightly controlled.
- More robust: Lane width and dosage alignment are maintained by mechanical design as well as process control.
What This Means for Your ODF Project
1. Lower Material Loss
With multi-formula lanes already shaped at the coating step, you no longer “create” strip geometry by cutting away large portions of the film. This is especially important for high-value APIs and specialty excipients, where edge scrap can become a major cost driver.
2. More Stable Content and Strip Width Uniformity
When each lane is defined by hardware geometry and controlled coating parameters, it is easier to:
- Keep strip width within tight tolerances across the full roll.
- Preserve dosage ratios between lanes (for example, API A on the left, API B on the right).
- Maintain a stable process window during scale-up from pilot runs to commercial campaigns.
3. Fewer Steps, Fewer Stops
A shorter, more integrated process means:
- Fewer intermediate rewinds and re-threading operations.
- Less time spent on cleaning and changeover between runs.
- Validation packages that are easier to explain to regulators, with a clear chain from formulation to film to sachet.
Recommended Equipment and Configurations
HUANGHAI’s strip-based multi-formula coating technology is implemented across both pilot-scale and commercial systems, so you can maintain the same logic from development through scale-up.
MJ150-L – Pilot and Medium-Scale Multi-Formula Coating
The MJ150-L ODF Film Coating Machine is designed for pilot-scale and medium-scale ODF production. It is ideal for:
- Establishing multi-formula coating windows and strip layouts.
- Optimising lane widths, viscosities and drying logic under controlled conditions.
- Preparing data and samples for registration, technology transfer and partner evaluations.
MJ150 – Commercial-Scale Multi-Formula ODF and Patch Production
For commercial output, the MJ150 ODF & Transdermal Patch Film Making Machine inherits the same core coating logic and supports high-throughput, multi-lane production. It is engineered for:
- Pharma-grade ODF combination products.
- Solvent-based transdermal patches using similar strip-based concepts.
- Integration with downstream slitting and high-speed pouching lines.
For a broader view of how these systems fit into a full line, see:
*Features Huanghai's exclusive patented hot-air drying technology (Patent No. CN201668734U) ensuring uniform bottom-up heating.
*Designed to meet Class I Div 1 / ATEX explosion-proof standards for safe transdermal solvent handling.
Conclusion: Making “One Film, Many Formulas” an Engineering Reality
The true competitiveness of multi-formula ODFs is not just about whether a formulation can be created in the lab. It comes from turning that formulation into a short, stable and verifiable manufacturing process.
HUANGHAI’s strip-based coating innovation, backed by patent CN117323228A, shifts complexity upstream into a structured coating architecture – reducing waste and process noise in the downstream steps. With MJ150-L and MJ150 working as a coherent pair, “one film, many formulas” becomes less of an experiment and more of a scalable, GMP-ready production strategy.
If you are evaluating multi-API or combination ODF projects and want to reduce risk during scale-up, our team can help design a multi-formula coating route tailored to your products and regulatory pathway.
Contact HUANGHAI to discuss how strip-based multi-formula coating can support your next ODF line.
\nFrequently Asked Questions
Q: What is the difference between an ODF film and a transdermal patch?
A: Oral Dissolving Films (ODF) are placed on or under the tongue and dissolve within seconds to minutes, delivering APIs directly through the oral mucosa or via swallowing. Transdermal patches adhere to the skin and deliver APIs through the dermal layers into systemic circulation over hours to days. Despite different delivery routes, both are manufactured using similar solvent-cast film coating processes. Huanghai's MJ150 ODF machine supports both applications on a single platform with approximately 2 working days of changeover time.
Q: What production output can I expect from a Huanghai ODF machine?
A: The MJ150 produces 20,000 films/hour at commercial scale. The MJ150-L targets R&D and pilot production at 8,000–10,000 films/hour. For fully integrated lines, pair either machine with the MJF180 automatic cutting and packaging system (11,900 films/hr) or the more affordable EZ320 (9,000 films/hr). A complete MJ150 + MJF180 line can produce over 150 million finished pouches annually on a single-shift basis. Contact us for pricing and configuration details.
Q: What drying technology does Huanghai use for ODF production?
A: Huanghai uses patented gradient hot-air drying (Patent CN201668734U), which applies a smooth progressive temperature drop rather than stepwise oven zones used by competitors. This results in more uniform film thickness, reduced edge curl, and better API distribution across the film web. An optional far-infrared heating module adds 20–30% drying efficiency for solvent-based formulations. This patented drying system is one of the key technical advantages that justifies Huanghai's position as the preferred ODF equipment supplier to Sinopharm, Shanghai Pharma, and Fosun Pharma.
Q: What are the GMP requirements for ODF production equipment?
A: ODF manufacturing equipment must comply with cGMP (21 CFR Parts 210/211) for US market products, and equivalent standards (EU GMP Annex 1, ChGMP) for other markets. Key requirements: material contact surfaces must be 316L stainless steel or equivalent; CIP/SIP capability or documented cleaning validation; data integrity controls meeting ALCOA+ principles (audit trails, access control). Huanghai ODF machines meet these standards—all product contact surfaces use pharmaceutical-grade materials, and the control system includes operator access logs and parameter change records. Request our GMP compliance documentation.
Q: Can Huanghai machines produce stripe-coated or multi-formula ODF films?
A: Yes. Huanghai holds a patent for multi-formula stripe coating (Patent CN117323228A), enabling two different API formulations to be applied side-by-side in a single coating pass. This eliminates the need for multiple coating/drying cycles when producing combination-drug ODF products. Competitors require manual multi-layer coating with drying intervals between each formula. This capability is particularly valuable for fixed-dose combination products (e.g., dual-API ODFs for cardiovascular or CNS indications) where coating efficiency directly impacts production economics.